YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced its financial results for the year and quarter ending December 31, 2024, ...

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth ...

It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Cassava Sciences, Inc ...

OptiNose (OPTN) delivered earnings and revenue surprises of 95.71% and 5.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to ...

OptiNose Inc. OPTN) on Wednesday reported a loss of $360,000 in its fourth quarter.

Reports Q4 revenue $22.418M, consensus $20.82M.Light Up your Portfolio with Spark:Easily identify stocks' risks and opportunities. Discover ...

The average of price targets set by Wall Street analysts indicates a potential upside of 143.1% in OptiNose (OPTN). While the effectiveness of this highly sought-after metric is questionable, the ...

These Stocks Are Moving the Most Today: FedEx, Nike, Micron, Boeing, Super Micro, NIO, Carnival, D-Wave Quantum, and More -- Barrons.com This article is a text version of a Wall Street Journal ...